Administration Information Sample Clauses

Administration Information. Entrust may store information in and related to Customer’s Order and Management Account and information generated by Customer’s usage of the Hosted Service, such as Customer’s access credentials, contact information for Agents, and entitlement consumption (“Administration Information”) in the United States and/or Canada, and may process Administration Information for the purposes of billing, providing Support and to investigate fraud, abuse or violations of this Agreement in the United States, Canada and other locations where Entrust maintains its support and investigation personnel.
Sample 1Sample 2Sample 3See All (7)
AutoNDA by SimpleDocs
Administration Information. Long-term If patients need pre-treatment with nebulised salbutamol 2.5mg, this can be mixed directly with colistin (immediately prior to use) and nebulised. Reference: Xxxxxxx XX, Xxxxxxx NR, Xxxxxxxx XX (1992) Cystic Fibrosis Inhalation Therapy: Stability of a Combined Salbutamol/Colistin Solution. Australian Journal of Hospital Pharmacy. 22(5):378-80 Initial specialist monitoring: • Spirometry pre and post the initial (test) dose. Ongoing specialist monitoring: • Sputum microbiology • On-going compliance and tolerance • Administration of the first (test) dose with lung function monitoring • Training the patient/carer in use of nebulised antibiotics • Prescription and supply (via hospital pharmacy) of the first month of colistin and diluents • Supply and ongoing maintenance of an appropriate nebuliser/compressor system • On-going supply of plastic syringes to measure diluent volumes • Assess response to treatment and to discontinue if no benefit • Ongoing clinical and microbiological review • On-going prescription of colistin and diluents (in plastic ampoules) • Diluents Diluents must be supplied in 5ml plastic ampoules for ease of use and to avoid the risks associated with breaking glass ampoules. Where part ampoules need to be used, volumes do not need to be measured accurately using a syringe, they can be estimated from the original volume in the vial. Recommended method of reconstitution: The method used for the test dose should be continued. Any change in the diluents used will require the test dose to be repeated. o Method 1: 5ml sodium chloride 0.9% o Method 2: 2ml water + 2ml sodium chloride 0.9% (least likely to cause bronchoconstriction) • Nebuliser and associated equipment (Pari LC or eFlow) This will be supplied by the hospital, and will be serviced / replaced when required. • Expiratory filters These are used while patients are in hospital to minimise risks of antibiotic resistance and staff sensitisation due to repeated exposure. At home the use of expiratory filters is not considered to be necessary provided the patient nebulises alone in a well ventilated room. If a particular patient wants to use filters they may be purchased direct from PARI Medical Limited. It is recommended that pets are not present in the room when nebulisation occurs. • Suspected side-effects / adverse reactions • Deterioration in clinical status • British Thoracic Society guideline for non-CF bronchiectasis. X X Xxxxxxx, X Xxxxxx, A T Xxxx. Thorax July 2010 • Britis...
Sample 1
Administration Information. If measuring ciclosporin trough levels, ask the patient to omit morning dose of ciclosporin. • Levels not needed for dermatological doses but may be indicated to check for toxicity. There is no correlation between efficacy of treatment in psoriasis and serum levels of ciclosporin. • Indefinite as long as efficacy and safety profiles are maintained. • Licensed for 8 weeks’ use in atopic dermatitis in patients aged over 16 years. • Check FBC, eGFR, ALT and albumin, BP and glucose, every 2 weeks, until a stable dose has been achieved for 6 weeks. • Watch creatinine if a NSAID is added (particularly diclofenac). Once the patient has been on a stable dose for 6 weeks: • check FBC, eGFR, ALT and albumin, BP and glucose every month for 3 months. Where there is a low risk of toxicity, onward monitoring may then be reduced to 3-monthly as a minimum, after discussion with the relevant consultant, and usually not in children or those at high risk of toxicity, with renal impairment. Risk factors for toxicity include: a history of adverse drug events; medical co-morbidities including renal and liver impairment (e.g. NAFLD) and malignancy; patients at the extremes of weight (BMI <18 or >30 kg/m2); old age (>80 years). Patients on concomitant DMARDs, especially leflunomide, should have monthly monitoring. Be aware that creatinine may increase if NSAID is added (particularly diclofenac). • Check blood pressure as above and act on abnormal readings If BP cannot be controlled, stop ciclosporin. • Rheumatology / Dermatology medical team are responsible for the initiation and six weeks’ prescription of ciclosporin at a stable dose. • Patient education will be undertaken within the Rheumatology/Dermatology multidisciplinary team. Pregnancy testing / contraceptive cover to be checked. • Advice regarding care in the sun. • Check FBC, eGFR, ALT and albumin, BP and glucose, every 2 weeks, until a stable dose has been achieved for 6 weeks. • Patient to ensure disease is controlled and drug efficacy. • Watch creatinine if a NSAID is added (particularly diclofenac). From six weeks after the stable dose has been commenced, to prescribe and monitor ciclosporin therapy, and to communicate adverse events to the appropriate Rheumatology/Dermatology Consultant.
Sample 1
Administration Information 
Sample 1Sample 2Sample 3See All (11)

Related to Administration Information

  • Union Information On a quarterly basis, the Employer shall provide the Union with the name, address, telephone number, hire date, classification, employment status, and pay rate of bargaining unit members.

  • Transaction Information The Adviser shall furnish to the Trust such information concerning portfolio transactions as may be necessary to enable the Trust or its designated agent to perform such compliance testing on the Funds and the Adviser’s services as the Trust may, in its sole discretion, determine to be appropriate. The provision of such information by the Adviser to the Trust or its designated agent in no way relieves the Adviser of its own responsibilities under this Agreement.

  • Verizon Information Upon request by CBB, Verizon shall make available to CBB the following information to the extent that Verizon provides such information to its own business offices: a directory list of relevant NXX codes, directory and Customer Guide close dates, and Yellow Pages headings. Verizon shall also make available to CBB, on Verizon’s Wholesale website (or, at Verizon’s option, in writing) Verizon’s directory listings standards and specifications.

  • Administrative information Time limit for receipt of tenders or requests to participate

  • Confidential Information Protections 4.1 At all times during and after the Employee’s employment, the Employee will hold in confidence and will not disclose, use, lecture upon, or publish any of Company’s Confidential Information (defined below), except as may be required in connection with the Employee’s work for Company, or as expressly authorized by the Board. The Employee will obtain the written approval of the Board before publishing or submitting for publication any material (written, oral, or otherwise) that relates to the Employee’s work at Company and/or incorporates any Confidential Information. The Employee hereby assigns to Company any rights the Employee may have or acquire in any and all Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Company and its assigns.

  • Information Reporting We may report your performance under this Agreement to credit reporting agencies, including your failure to make minimum payments on time. A negative credit report may significantly harm your ability to obtain credit from other sources. We may also obtain follow-up credit reports on you (for example, when we review your Account for a credit line increase). We may exchange information about you or your Account with our affiliates, and, to the extent permitted by law, with other third parties. However, if you prefer that we not share such information with our affiliate companies, just call us at (000) 000-0000 or outside the Albuquerque area, 0-000-000-0000. You may also write to us at Nusenda Federal Credit Union, P.O. Box 8530, Albuquerque, New Mexico 87198. Closing Your Account. You may close your Account at any time by notifying us in writing. However, you remain responsible to pay the balance according to the terms of this Agreement. We may close your Account or suspend your Account privileges at any time without prior notice. We may also reissue a different Card, Account number, or different checks at any time. You must return the Card or the checks to us upon request. Lost or Stolen Cards. If any Card, Account Number or PIN is lost or stolen, or if you think someone used or may use them without your permission, notify us at once by calling the telephone number shown on the billing statement or by calling 0-000-000-0000. We may require you to provide certain information in writing to help us find out what happened. Do not use the Card after we've been notified, even if it is found or returned. You will not be liable for any unauthorized purchases or cash advances made after we've been notified of the loss or the theft; however, you must identify for us the charges on the billing statement that were not made by you or someone authorized by you, and from which you received no benefit. Credit Authorizations. We are not responsible if we do not approve a purchase or cash advance on your Account, or if a third party refuses to accept or honor the Card, even if you have sufficient credit available. We may limit the number of purchases or cash advances which may be approved in one day. If we detect unusual or suspicious activity on your Account, we may temporarily suspend your credit privileges until we can verify the activity. We may approve purchases or cash advances that cause the balance to exceed your credit line without waiving any of our rights under the Agreement. Waiver. Our failure to exercise, or our delay in exercising any of our rights under this Agreement for any reason does not mean that we will be unable to exercise these rights later.

  • Information Confidential As partial consideration for the granting of the Award hereunder, you hereby agree to keep confidential all information and knowledge, except that which has been disclosed in any public filings required by law, that you have relating to the terms and conditions of this Agreement; provided, however, that such information may be disclosed as required by law and may be given in confidence to your spouse and tax and financial advisors. In the event any breach of this promise comes to the attention of the Company, it shall take into consideration that breach in determining whether to recommend the grant of any future similar award to you, as a factor weighing against the advisability of granting any such future award to you.

  • Information Management Information and Records

  • Information/Cooperation Executive shall, upon reasonable notice, furnish such information and assistance to the Bank as may be reasonably required by the Bank, in connection with any litigation in which it or any of its subsidiaries or affiliates is, or may become, a party; provided, however, that Executive shall not be required to provide information or assistance with respect to any litigation between Executive and the Bank or any other subsidiaries or affiliates.

  • Information The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer or its advisors. The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, afforded the opportunity to ask questions of the Company. Notwithstanding the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer. Neither such inquiries nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below. The Buyer understands that its investment in the Securities involves a significant degree of risk. The Buyer is not aware of any facts that may constitute a breach of any of the Company's representations and warranties made herein.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!